Evidence map›Paper›PMID 39460478›Full record

SynthesisJournal of evidence-based integrative medicine

The Effects of Coffee/Caffeine in Patients with Multiple Sclerosis; A Systematic Review.

Shabnam Salekzamani, Saman Baharomid, Sina Pakkhesal, Maryam Balafkandeh, Elnaz Gholipour-Khalili, Mahnaz Talebi, Sarvin Sanaie, Amirreza Naseri

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of evidence-based integrative medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shabnam SalekzamaniDepartment of Nutrition, Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran.
Saman BaharomidStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Sina PakkhesalStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Maryam BalafkandehStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
Elnaz Gholipour-KhaliliMedical Faculty, Yeditepe University, Istanbul, Türkiye.
Mahnaz TalebiNeurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Sarvin SanaieNeurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Amirreza NaseriStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0001-9723-0109

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis (MS) is a demyelinating disease of the central nervous system. Caffeine, as the most widely consumed psychoactive substance, has been suggested to have potential effects on the clinical course and disability levels of MS patients. This study aimed to review the current evidence on the effects of coffee/caffeine in patients with MS.

methodsThis study followed the Joanna Briggs Institute (JBI) Manual for Evidence Synthesis and PRISMA 2020 statement. Clinical evidence regarding the effects of caffeine/coffee in MS patients was considered. A systematic search was performed in PubMed, Scopus, Web of Science, and Embase in October 2023, and updated via handsearching in March 2024. JBI's critical appraisal tools were utilized to scrutinize the risk of bias.

resultsOut of 297 screened records, eight studies were eventually found to meet our inclusion criteria. The sample size of the studies varied between 12 and 1372 and the study designs were retrospective cohort, RCT, single-blind crossover trial, single-arm pilot study (each one study), and cross-sectional (four studies). No significant association between the level of disability and coffee/caffeine intake has been reported, although it was reported to be associated with cognitive improvements. DISCUSSION: Evidence indicates an association between coffee/caffeine consumption, and improved cognitive outcomes in patients with MS, while there is no considerable relationship with the disease disability. Considering the limitations of the evidence, such as the small number of studies, and great diversity in study designs, the findings of this study should translate to clinical practice with caution.

Indexed as

CaffeineCoffeeMultiple SclerosisHumansCaffeineCoffeecaffeinecoffeecognitioncognition disordersmultiple sclerosissystematic review

Identifiers

PMID39460478
PMCPMC11514122

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.